Now's the time to find biomarkers on purpose

被引：2
作者：
Auman, J. T. [1 ]
McLeod, H. L. [1 ]
机构：
[1] Univ N Carolina, Inst Pharmacogenom & Individualized Therapy, Chapel Hill, NC 27515 USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷 / 02期
关键词：
CELL LUNG-CANCER; BREAST-CANCER; EGFR; RESISTANCE; ERLOTINIB; GEFITINIB; KRAS;
D O I：
10.1093/annonc/mdp571
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：193 / 194
页数：2
相关论文
共 9 条
[1]   Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity [J].
Auman, J. Todd ;
McLeod, Howard L. .
DRUG METABOLISM REVIEWS, 2008, 40 (02) :303-315
[2]   EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].
Kobayashi, S ;
Boggon, TJ ;
Dayaram, T ;
Janne, PA ;
Kocher, O ;
Meyerson, M ;
Johnson, BE ;
Eck, MJ ;
Tenen, DG ;
Halmos, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792
[3]   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].
Lynch, TJ ;
Bell, DW ;
Sordella, R ;
Gurubhagavatula, S ;
Okimoto, RA ;
Brannigan, BW ;
Harris, PL ;
Haserlat, SM ;
Supko, JG ;
Haluska, FG ;
Louis, DN ;
Christiani, DC ;
Settleman, J ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139
[4]   Implications for KRAS status and EGFR-targeted therapies in metastatic CRC [J].
Normanno, Nicola ;
Tejpar, Sabine ;
Morgillo, Floriana ;
De Luca, Antonella ;
Van Cutsem, Eric ;
Ciardiello, Fortunato .
NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (09) :519-527
[5]   Erlotinib in previously treated non-small-cell lung cancer [J].
Shepherd, FA ;
Pereira, JR ;
Ciuleanu, T ;
Tan, EH ;
Hirsh, V ;
Thongprasert, S ;
Campos, D ;
Maoleekoonpiroj, S ;
Smylie, M ;
Martins, R ;
van Kooten, M ;
Dediu, M ;
Findlay, B ;
Tu, DS ;
Johnston, D ;
Bezjak, A ;
Clark, G ;
Santabárbara, P ;
Seymour, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132
[6]   HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].
SLAMON, DJ ;
CLARK, GM ;
WONG, SG ;
LEVIN, WJ ;
ULLRICH, A ;
MCGUIRE, WL .
SCIENCE, 1987, 235 (4785) :177-182
[7]   A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer [J].
Tan, E. -H. ;
Ramlau, R. ;
Pluzanska, A. ;
Kuo, H. -P. ;
Reck, M. ;
Milanowski, J. ;
Au, J. S. -K. ;
Felip, E. ;
Yang, P. -C. ;
Damyanov, D. ;
Orlov, S. ;
Akimov, M. ;
Delmar, P. ;
Essioux, L. ;
Hillenbach, C. ;
Klughammer, B. ;
McLoughlin, P. ;
Baselga, J. .
ANNALS OF ONCOLOGY, 2010, 21 (02) :217-222
[8]   Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer [J].
Valabrega, G. ;
Montemurro, F. ;
Aglietta, M. .
ANNALS OF ONCOLOGY, 2007, 18 (06) :977-984
[9]   Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21 [J].
Zhu, Chang-Qi ;
Santos, Gilda da Cunha ;
Ding, Keyue ;
Sakurada, Akira ;
Cutz, Jean-Claude ;
Liu, Ni ;
Zhang, Tong ;
Marrano, Paula ;
Whitehead, Marlo ;
Squire, Jeremy A. ;
Kamel-Reid, Suzanne ;
Seymour, Lesley ;
Shepherd, Frances A. ;
Tsao, Ming-Sound .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) :4268-4275
1